Erasca (ERAS) Cash from Investing Activities Growth (3y) (2023 - 2026)
Erasca (ERAS) Cash from Investing Activities Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -39.73% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 296.32% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -53.57% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -246.81% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.84% |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 29.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.65% |
| Mar 31, 2026 | -164.82% |
| Dec 31, 2025 | 91.99% |
| Sep 30, 2025 | 35.09% |
| Jun 30, 2025 | 54.85% |
| Mar 31, 2025 | 176.33% |
| Dec 31, 2024 | 33.02% |
| Sep 30, 2024 | -174.89% |
| Jun 30, 2024 | -177.72% |
| Mar 31, 2024 | 299.06% |
| Dec 31, 2023 | -35.02% |
| Sep 30, 2023 | 66.72% |